CompletedPhase 2NCT00362440
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beth Israel Deaconess Medical Center
- Principal Investigator
- Christos Mantzoros, MDBeth Israel Deaconess Medical Center
- Intervention
- Leptin(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2011
Study locations (1)
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Collaborators
American Diabetes Association
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00362440 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024University of Michigan
- RECRUITINGNCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryAmryt Pharma
See all trials for Lipodystrophy due to peptidic growth factors deficiency →